Pila Pharma AB (publ) (STO:PILA)

Market Cap	69.35M -24.8%
Revenue (ttm)	1.13M +42.7%
Net Income	-16.86M
EPS	-0.62
Shares Out	45.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	455,148
Average Volume	110,593
Open	1.438
Previous Close	1.350
Day's Range	1.350 - 1.800
52-Week Range	1.024 - 4.095
Beta	0.21
RSI	63.67
Earnings Date	Mar 19, 2026

About Pila Pharma AB

Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PILA

Financial Performance

In 2025, Pila Pharma AB's revenue was 1.13 million, an increase of 42.68% compared to the previous year's 789,889. Losses were -16.86 million, 50.0% more than in 2024.